Welcome to our dedicated page for Maxcyte news (Ticker: MXCT), a resource for investors and traders seeking the latest updates and insights on Maxcyte stock.
MaxCyte, Inc. reports news on its cell-engineering technology business for biotechnology and pharmaceutical customers developing next-generation cell therapeutics. Company updates center on Flow Electroporation technology, ExPERT instruments, SeQure gene editing assessment services, and Strategic Platform License relationships that can generate product, license, research, clinical and program-related revenue.
Recurring developments include quarterly and annual financial results, revenue guidance, installed instrument activity, licensed customer programs, product launches such as ExPERT DTx for high-throughput electroporation, and corporate governance matters including executive appointments and equity compensation grants.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
MaxCyte, a leader in cell-engineering technology, announced it will release its financial results for the first quarter of 2023 on May 10, 2023, after the U.S. market close. A conference call will follow at 4:30 p.m. ET to discuss these results. MaxCyte's ExPERT platform, which employs Flow Electroporation technology, supports the growing cell therapy market, aiding in the discovery and commercialization of next-generation cell-based medicines. The company aims to leverage its platforms to improve patient outcomes and has built a robust intellectual property portfolio to enhance its innovative capabilities. Interested investors can register for the call and find live updates on MaxCyte's website.
MaxCyte, a cell-engineering company, has appointed Douglas J. Swirsky as its new Chief Financial Officer effective immediately. With over two decades of experience, Swirsky's previous roles include CFO of AavantiBio and leadership positions at Rexahn Pharmaceuticals and GenVec. The President of MaxCyte expressed enthusiasm about Swirsky’s extensive financial expertise and its potential influence on the company's growth. Concurrently, Ron Holtz, the former CFO, transitions to EVP of Administration after nearly 18 years of service. The company aims to leverage Swirsky's insights to enhance financial operations and shareholder value.
MaxCyte, Inc. (NASDAQ: MXCT) reported a 31% total revenue growth for the full year 2022, reaching $44.3 million. In Q4 2022, total revenue was $12.4 million, up 22% year-over-year. Core business revenues saw 26% growth, driven by a 33% increase in cell therapy revenue. The company anticipates 2023 revenue growth between 21% and 26%, with core growth expected between 20% and 25%. Total cash and equivalents stood at $227.3 million. MaxCyte's partnerships have expanded, with 19 active SPL partnerships and significant potential for pre-commercial milestone payments exceeding $1.55 billion.